Table 5. Randomized Studies in Stage III Pancreatic Cancer: Median Survival
| Trial | Regimen | Chemoradiation | Radiation Alone | Chemotherapy Alone | P Value |
| 5 FU = 5-fluorouracil; ECOG = Eastern Cooperative Oncology Group; FFCD = Fédération Francophone de Cancérologie Digestive; GEM = gemcitabine; GITSG = Gastrointestinal Tumor Study Group; Gy = gray (unit of absorbed radiation of ionizing radiation); P value = probability value; XRT = x-ray or radiation therapy. | |||||
| Pre-2000 | |||||
| GITSG[3] | Radiation alone vs. 5-FU/60 Gy XRT | 40 weeks | 20 weeks | <.01 | |
| ECOG[4] | Radiation vs. 5-FU, mitomycin C/59 Gy XRT | 8.4 months | 7.1 months | .16 | |
| Post-2000 | |||||
| FFCD[5] | GEM vs. GEM, cisplatin, 60 Gy XRT | 8.6 months | 13 months | .03 | |
| ECOG[6] | GEM vs. GEM/50.4 Gy XRT | 11.1 months | 9.2 months | .017 | |
References
- A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg 189 (2): 205-8, 1979. [PUBMED Abstract]
- Cohen SJ, Dobelbower R Jr, Lipsitz S, et al.: A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62 (5): 1345-50, 2005. [PUBMED Abstract]
- Chauffert B, Mornex F, Bonnetain F, et al.: Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCD-SFRO study. [Abstract] J Clin Oncol 24 (Suppl 18): A-4008, 180s, 2006.
- Loehrer PJ Sr, Feng Y, Cardenes H, et al.: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29 (31): 4105-12, 2011. [PUBMED Abstract]
